Bridge Biotherapeutics Inc. (288330 KO) stock market data APIs
₩4610
-30(-0.6%)
as of January 10, 2025
Bridge Biotherapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Prev. Close
4640
Open
4610
Volume
1 258 K
High
4705
Low
4465
52 wk Range
1451.3001-6100
Market Cap
0
Shares Outstanding
0
Revenue
0
EPS
-105.0104
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Bridge Biotherapeutics Inc. data using free add-ons & libraries
Get Bridge Biotherapeutics Inc. Fundamental Data
Bridge Biotherapeutics Inc. Fundamental data includes:
- Net Revenue: 0
- EBITDA: 0
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-09-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bridge Biotherapeutics Inc. News
New
Bridge Biotherapeutics to Present Updated Preclinical Data of BBT-207 at the AACR 2023 Annual Meeting
The abstract of BBT-207 preclinical studies is now available on the AACR website Preclinical data suggests that BBT-207 may have the potential to be used as a broad-spectrum fourth generation EGFR TKI...
Bridge Biotherapeutics Presents Phase 2a Clinical Trial Results For BBT-401, a Drug Candidate to Treat Ulcerative Colitis
BBT-401 meets safety endpoints achieved in previous clinical studies The drug candidate did not achieve an improved clinical response compared to the placebo study group 54.5% of the treatment cohort ...
Bridge Biotherapeutics to Present at BIOTECH SHOWCASE™ 2023
SAN FRANCISCO and SEONGNAM, South Korea, Jan. 3, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis and i...
Bridge Biotherapeutics Initiates Phase 2 Clinical Trial of BBT-877 in Patients with Idiopathic Pulmonary Fibrosis
The Phase 2 study will evaluate the efficacy, safety, and tolerability of BBT-877 in idiopathic pulmonary fibrosis patients Data from the Phase 1 clinical study demonstrated LPA inhibition of up to 90...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
